Log In
Print this Print this

SGN-LIV1A (formerly Anti-LIV-1 ADC)

  Manage Alerts
Collapse Summary General Information
Company Seattle Genetics Inc.
DescriptionAntibody-drug conjugate (ADC) composed of a humanized anti-solute carrier family 39 zinc transporter member 6 (SLC39A6; LIV-1; ZIP6) mAb and monomethyl auristatin E (MMAE)
Molecular Target Solute carrier family 39 zinc transporter member 6 (SLC39A6) (LIV-1) (ZIP6)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationBreast cancer
Indication DetailsTreat LIV-1-positive metastatic breast cancer; Treat triple-negative breast cancer (TNBC)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today